Malignant Melanoma | Access and Reimbursement | US | 2016
Combination therapies are transforming the malignant melanoma treatment landscape, raising the efficacy bar for emerging therapies. However, combination therapies have increased the cost of malignant melanoma treatment and drug manufacturers are under increasing pressure to justify the value of their therapy. In order to optimize market access, manufacturers need to understand the reimbursement dynamics in this market (e.g. the impact of payer-imposed restrictions, risk-sharing agreements, and patient assistance programs) and draw on insights from the successes and setbacks of current key malignant melanoma brands.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
